Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

MAPK Signaling Cascades01:07

MAPK Signaling Cascades

9.0K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.0K
Cancer Cell Migration through Invadopodia01:35

Cancer Cell Migration through Invadopodia

3.4K
Invadosome is a broad category of cell surface structures with proteolytic activity that  degrades the extracellular matrix (ECM). Invadosomes are present in normal cell types, including macrophages, endothelial cells, and neurons, as well as tumor cells. Although the macrophage podosomes and tumor cell invadopodia are classified as invadosomes, they have different structures, molecular pathways, and functions. Podosomes are short structures that last for a few minutes. However,...
3.4K
Metastasis02:30

Metastasis

6.8K
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
6.8K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

8.3K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
8.3K
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal01:22

Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal

2.8K
Erythropoietin-producing hepatocellular carcinoma receptor (Eph) and its ligand, Eph receptor-interacting protein (Ephrin) were first discovered in the human carcinoma cell line, hence the name. Ephrin-Eph interaction guides cells to reach their appropriate location in adult tissues. They also play an essential role in the immune system by helping in immune cell migration, adhesion, and activation. Based on their structure and function, Eph is divided into two classes — EphA and EphB.
2.8K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Educational Interventions for the Timely Diagnosis of Pediatric Patients With Cancer: A Scoping Review.

JCO global oncology·2026
Same author

Landscape Assessment to Characterize Baseline Access and Multilevel Barriers to IMProve Access to Chimeric Antigen Receptor T-Cell CD19 Therapy for Pediatric B-ALL (IMPACT study) Across Europe.

JCO global oncology·2026
Same author

Ethnic and Socioeconomic Factors Associated with Locally Advanced Retinoblastoma: A Retrospective Study.

Ocular oncology and pathology·2026
Same author

Clofarabine for relapsed/refractory Langerhans cell (LC) and non-LC histiocytosis.

Blood advances·2026
Same author

Disease extent, not lesion location, determines relapse risk in single-system skeletal Langerhans cell histiocytosis.

Blood advances·2026
Same author

Treatment Decision Making at Diagnosis for Children Presenting With Advanced Cancer in Low- and Middle-Income Countries.

JCO global oncology·2026

Related Experiment Video

Updated: Mar 16, 2026

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.7K

Caveolin-1 promotes Ewing sarcoma metastasis regulating MMP-9 expression through MAPK/ERK pathway.

Laura Lagares-Tena1, Silvia García-Monclús1, Roser López-Alemany1

  • 1Sarcoma Research Group, Institut d'Investigació Biomèdica de Bellvitge-IDIBELL, L'Hospitalet de Llobregat, Barcelona, Spain.

Oncotarget
|August 4, 2016
PubMed
Summary

Caveolin-1 (CAV1) drives Ewing sarcoma (ES) metastasis by activating MEK/ERK and IQGAP1. Silencing CAV1 or IQGAP1 reduces cell invasion, revealing new therapeutic targets for this pediatric cancer.

Keywords:
Ewing sarcomacaveolin-1mapkmetastasismmp9

More Related Videos

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.5K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.7K

Related Experiment Videos

Last Updated: Mar 16, 2026

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells
11:15

A Preclinical Mouse Model of Osteosarcoma to Define the Extracellular Vesicle-mediated Communication Between Tumor and Mesenchymal Stem Cells

Published on: May 6, 2018

10.7K
An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells
08:54

An Immunofluorescent Method for Characterization of Barrett’s Esophagus Cells

Published on: July 20, 2014

14.5K
Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma
08:07

Three-Dimensional Bone Extracellular Matrix Model for Osteosarcoma

Published on: April 12, 2019

7.7K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Metastasis

Background:

  • Ewing sarcoma (ES) is a pediatric bone and soft tissue cancer.
  • Caveolin-1 (CAV1) is a key oncogenic driver in ES, promoting metastasis via matrix metalloproteinase-9 (MMP-9).

Purpose of the Study:

  • To elucidate the molecular mechanisms by which CAV1 promotes ES metastasis.
  • To identify novel therapeutic targets for inhibiting ES progression.

Main Methods:

  • CAV1 and IQGAP1 silencing in ES cell lines.
  • Analysis of MEK/ERK and RPS6 phosphorylation.
  • Assessment of MMP-9 expression and activity.
  • In vitro migration and invasion assays.
  • In vivo metastasis studies using an orthotopic model.

Main Results:

  • CAV1 silencing reduced MEK/ERK phosphorylation and MMP-9 activity, inhibiting migration and invasion.
  • IQGAP1 silencing similarly decreased MEK/ERK phosphorylation and MMP-9 expression, reducing cell invasiveness.
  • CAV1 and IQGAP1 were found in close proximity at the cell edge, suggesting IQGAP1 links CAV1 to MEK/ERK signaling.
  • RSK1, downstream of ERK, was implicated in metastasis, as RSK1 silencing reduced in vitro invasion and in vivo metastasis incidence.

Conclusions:

  • CAV1 drives ES metastasis through IQGAP1 and MEK/ERK signaling, impacting MMP-9.
  • RSK1 plays a role in ES cell migration, invasion, and metastasis.
  • This study identifies CAV1, IQGAP1, and RSK1 as potential therapeutic targets for combating ES metastasis.